T he humoral component of acquired immunity was discovered by Emil von Behring and Shibasaburo Kitasato about a century ago during their work on serum therapy against diphtheria. Their findings were rapidly exploited, and serotherapy saved thousands of lives from infectious diseases. Acquired humoral immunity is also the primary mechanism underlying the protective effect afforded by current vaccines against infectious diseases. The persistence of acquired humoral immunity after an immune challenge can be remarkably long lasting. Levels of specific antibodies toward tetanus or diphtheria displayed half-lives of 11-19 years and up to 500-3,000 years for mumps and measles (Amanna et al, 2007) . The maintenance of acquired humoral immunity after vaccination or resolution of an infection results from the formation of long-lived memory B cells and plasma cells.
After an immune challenge, activated B cells can differentiate into memory B cells and long-lived plasma cells in the germinal centers that develop within the B-cell follicles under the command of T-cell-dependent processes. Indeed, CD4
+ T cells provide cognate B cells with the helper signals required for their initiation of the germinal center reaction and subsequently for their survival and final differentiation. T-cell help is considered a major limiting factor for the germinal center response. A key goal in vaccinology is therefore to characterize the T helper cell driving the germinal center reaction and to identify the mechanisms underlying their differentiation. A major breakthrough was the identification of T follicular helper (T FH ) cells, a specific CD4 + T-cell subset that characteristically expresses the master transcription factor Bcl-6, and the chemokine receptor CXCR5, which allows their migration into B-cell follicles where the chemokine CXCL13 is produced by follicular dendritic cells (Crotty, 2011) . Evidence is accumulating that T FH cells can become memory cells (Weber et al, 2012) . In the sole absence of these T cells, germinal centers, memory B cells, and long-lived plasma cells fail to develop efficiently. The study by Chakarov and Fazilleau published in this issue of EMBO Molecular Medicine provides important new findings on the signals and cells that can promote T FH -cell differentiation (Chakarov & Fazilleau, 2014) . The current trend in vaccination relies on the usage of highly purified antigens combined with adjuvants that stimulate optimal adaptive immune responses. Toll-like receptor (TLR) agonists constitute a particularly promising class of adjuvants because they can stimulate both innate and adaptive immunity and are thought to promote potent long-term protection. Consistent with this view, one of the most successful vaccines, the live attenuated yellow fever vaccine 17D, has a remarkable capacity to stimulate multiple TLRs. The TLR9 agonists comprising CpG-containing DNA oligonucleotides have been the focus of intense interest for the production of better vaccines for humans. Addition of a CpG oligonucleotide (called CpG 7909 or CpG 2006) to a hepatitis B vaccine induced a long-lasting protective antibody response in HIV-infected subjects who had previously failed to respond to the same vaccine in the absence of such adjuvant (Cooper et al, 2005) . The study of Chakarov and Fazilleau addresses how CpG improves the development of acquired humoral immunity toward protein antigens. Following the observation that CpG increased the formation of antigen-reactive T FH cells in various immunization regimens, they examined which cell type was responsible for this effect. 
"CpG increased the formation of antigen-reactive T FH cells in various immunization
regimens " trials) preferentially activates B cells (and few specific dendritic cell (DC) subsets), suggesting that it might promote T FH -cell formation via intrinsic signaling in B cells, which express TLR9 and can contribute to the formation of T FH cells. However, Chakarov and Fazilleau found comparable formation of antigen-specific T FH cells in wild-type and B-cell-deficient mice, which also displayed similar T FH -cell number increase when CpG was added to the immunization cocktail. These findings confirm previous observation that T FH -cell differentiation can occur in the absence of B cells (Choi et al, 2011) . DCs were an obvious next candidate. T-cell accumulation in B-cell follicles is regulated by DCs and is independent of B-cell activation (Fillatreau & Gray, 2003) . A previous study performed using mice with a conditional deletion of the major TLR signaling adaptor MyD88, which is strictly required for TLR9 signaling in distinct cell types, found that intrinsic MyD88 signaling was required in DCs, but not in B cells, for the enhancing effect of CpG on antibody production in response to immunization with protein antigens. Although the formation of T FH cells was not examined in that study, its conclusions are in agreement with the notion that it is intrinsic TLR signaling in DCs, rather than in B cells, that drives the increased formation of T FH cells in response to CpG after immunization with protein antigens. Consistent with this, mice in which only CD11c + DCs expressed MHC-II could generate T FH cells (Goenka et al, 2011 (Choi et al, 2011) . At this stage of the immune response, a large fraction of the primed T cells is certainly uncommitted. In fact, some activated T cells might persist in an unpolarized state throughout the immune response. The monocyte-derived DCs might create a microenvironment promoting the engagement of such 'undecided' T cells into the T FH -cell taskforce. An alternative possibility is that CpG induced a T FH -cell profile in cells that were about to initiate their engagement in another differentiation pathway. In this case, CpG would promote T FHcell formation at the expense of other subsets of polarized T helper cells, which could be attractive to promote humoral immunity while limiting potentially unwanted inflammatory T-cell responses. Such shift in the T-cell subset balance could involve an inhibitory effect of Bcl-6, the master transcription factor of T FH cells, on the expression of Blimp-1, which contributes to the formation of other T effector subsets. Further studies are required to distinguish between these possibilities and to delineate when monocyte-derived DCs and conventional DCs, respectively, interact with antigen-reactive T cells, which might precise the various DC-T-cell choreographies leading to T FH -cell formation. In any case, the T cells induced into T FH cells under the influence of CpG seem functional because their accumulation was linked to a concomitant augmentation of the adaptive humoral response. The identification of monocyte-derived DCs as booster of the T FH -cell response suggests that it could be possible to boost the protective value of vaccines by targeting these cells. A human equivalent of monocyte-derived DCs was recently identified (Segura et al, 2013) . Moreover, Chakarov and Fazilleau showed that antigens enclosed in vesicles specifically internalized by monocyte-derived DCs efficiently promoted humoral immunity. However, they did not directly compare side-by-side soluble antigen delivery versus antigen enclosed in beads for their capacities to promote T FH -cell formation and long-lasting humoral immunity so it is not yet possible to conclude whether such mode of antigen delivery actually presents a specific advantage in terms of vaccine efficacy. An important point to keep in mind with regard to the targeting of such DCs is, however, that DCs derived from Ly6C + blood monocytes are very plastic and also able to promote T H 1-as well as T H 2-cell responses depending on the inflammatory environment. Moreover, the human monocyte-derived DCs recently identified in the synovial fluid of rheumatoid arthritis patients and ascites fluid from cancer patients were potent inducers of T H 17-cell differentiation in vitro (Segura et al, 2013 (Geeraedts et al, 2008; Hou et al, 2011) . Such ongoing progress in our understanding of the modes of action of adjuvant shall allow the development of safer and more efficient vaccines.
